LSI part of multi-institute effort to develop new treatments for influenza infection

The Laboratory for Synthetic Immunity is part of a $21.9 million award from DARPA to develop gene therapies to enable protection against a wide range of influenza strains and improve immune responses and efficacy of current influenza vaccines. The work, led by Phil Santangelo at Georgia Tech, is being performed by researchers at GT, Duke, Emory, UGA, ULL, Rockefeller, Acorda Therapeutics, and the CDC.

Learn more about the project here and here.